207 related articles for article (PubMed ID: 17332973)
21. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
22. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
23. Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents.
Bourré-Tessier J; Arino-Torregrosa M; Choquette D
Clin Rheumatol; 2014 Aug; 33(8):1049-53. PubMed ID: 24554383
[TBL] [Abstract][Full Text] [Related]
24. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
Bray MG; Poulain C; Dougados M; Gossec L
Joint Bone Spine; 2010 Mar; 77(2):135-41. PubMed ID: 20097592
[TBL] [Abstract][Full Text] [Related]
25. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
26. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
[TBL] [Abstract][Full Text] [Related]
27. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
[TBL] [Abstract][Full Text] [Related]
28. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
[TBL] [Abstract][Full Text] [Related]
29. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
30. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
31. Isoniazid hepatotoxicity in renal transplant recipients.
Antony SJ; Ynares C; Dummer JS
Clin Transplant; 1997 Feb; 11(1):34-7. PubMed ID: 9067692
[TBL] [Abstract][Full Text] [Related]
32. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
33. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
34. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.
Chen DY; Shen GH; Chen YM; Chen HH; Hsieh CW; Lan JL
Ann Rheum Dis; 2012 Feb; 71(2):231-7. PubMed ID: 22021896
[TBL] [Abstract][Full Text] [Related]
35. Short-course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapy.
Valls V; Ena J
Clin Rheumatol; 2015 Jan; 34(1):29-34. PubMed ID: 24464437
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
37. Is isoniazid safe for liver transplant candidates with latent tuberculosis?
Stucchi RS; Boin IF; Angerami RN; Zanaga L; Ataide EC; Udo EY
Transplant Proc; 2012 Oct; 44(8):2406-10. PubMed ID: 23026607
[TBL] [Abstract][Full Text] [Related]
38. Follow-up results of isoniazid chemoprophylaxis during biological therapy in Colombia.
Cataño JC; Morales M
Rheumatol Int; 2015 Sep; 35(9):1549-53. PubMed ID: 25763992
[TBL] [Abstract][Full Text] [Related]
39. [Isoniazid prophylaxis for pulmonary tuberculosis in Chinese patients with rheumatoid arthritis receiving long-term methotrexate therapy].
Xie QB; Wen FQ; Yin G
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):138-40. PubMed ID: 19292064
[TBL] [Abstract][Full Text] [Related]
40. Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test?
Alaşan F; Güleç Balbay E; Cangür Ş; Balbay Ö; Yılmaz Aydın L; Annakkaya AN
Aging Male; 2020 Dec; 23(5):1109-1114. PubMed ID: 31615316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]